Would You like a feature Interview?
All Interviews are 100% FREE of Charge
Leading biotechnology company Regeneron Pharmaceuticals (REGN) has shown strong financial growth in recent years. With promising prospects in the biotech industry, this stock could now be a solid portfolio addition. Read….
Biotechnology company Regeneron Pharmaceuticals, Inc. (REGN) could be a great addition to any portfolio before Q1 results are out next week. The biotech powerhouse has enjoyed great economic success in recent years.
REGN Earnings, EBIT, and net profit are growing at a CAGR of 22.9%, 31.2%, and 27% respectively over the past three years. Its EPS increased at a CAGR of 27.5% over the same period.
Additionally, the biotechnology industry is booming due to an aging population and rising chronic diseases. The global biotechnology market is expected to be worth approximately $1.68 trillion by 2030 and is growing. 8.7% CAGR.
Against this background, let’s discuss the company’s key financial indicators.
REGN Revenue, Gross Margin and Return on Assets Trends
REGN’s net income showed significant growth across the series, increasing from $298.4 million on June 30, 2020 to $807.5 million on December 31, 2021, an increase of 170%. Net income peaked at $873.6 million on March 31, 2022 before declining to $433.8 million by December 31, 2022, down 50.3%.
REGN has seen an overall upward trend in revenue since June 2020, with its most recent revenue reported in December 2022 at $1.22 billion, up from its first reported revenue of $7.9 billion in June 2020. It shows a growth rate of about 53% from $90 million. Revenue increased significantly from June. From 2021 to September 2021, it increased from $1.23 billion to $1.35 billion, declining slightly in subsequent quarters and reaching its current level at the end of 2022.
REGN’s gross margin declined steadily from 88.2% on June 30, 2020 to 84.8% on December 31, 2021, followed by a relatively steady growth trend, reaching reached 87.2%.
From June 2020 to December 2022, REGN ROA shows an overall upward trend. ROA increased from 0.203 in June 2020 to 0.366 in December 2021, representing an 80% growth over the period. In the most recent quarter from December 2021 to March 2022, ROA decreased slightly from 0.366 to 0.327. Current ROA is 0.157.
REGN’s Accelerating Stock Rise
REGN’s stock price is trending upward overall, increasing from $716.60 on December 30, 2022 to $826.56 on April 6, 2023. Growth appears to be accelerating as stocks rose more rapidly between March 10th and April 27th. , higher than 2023 from 4 November 2022 to 24 February 2023. Here is a chart of his REGN prices over the last 180 days.
Quality, Momentum, and Stability: REGN’s POWR Rating
REGN has an overall B rating, which means you buy with our proprietary patents. POWR rating system.At the time of writing, REGN is biotech This is the 19th category out of 383 stocks, and the lower the value, the higher the rank, so it is relatively good.
REGN’s POWR rating has an average score of 86 from October 2022 to April 2023, indicating quality is the highest rating. Momentum also consistently scores highly, ranging from 13 to 35 over the six months.
Stability was rated with the lowest score, with an average score of just 35 out of 100. Stability is trending downward overall, with a score of 20 in October 2022 and a low score of 41 in April 2023.
How does Regeneron Pharmaceuticals Inc. (REGN) compare to its peers?
Another stock in the biotech sector that might be worth considering is Biogen.BIIB), Gilead Sciences (guild), and Vanda Pharmaceuticals Inc. (VNDA) — Excellent POWR rating.
The bear market is not over…
That’s why you should find this timely presentation with trading plans and top picks from 40-year investment veteran Steve Lightmeister.
Revision: Stock Market Outlook 2023 >
REGN shares traded at $781.97 per share on Thursday morning, up $3.97 (+0.51%). Year-to-date, REGN is up his 8.38%, while the benchmark S&P 500 index is up his 7.25% over the same period.
About the Author: Anushka Dutta
Anushka is an analyst whose interest in understanding the impact of broader economic changes on financial markets motivated her to pursue a career in investment research.
post A Prescription For Success: Check Out This Week’s Strong Pharmaceutical Stocks first appeared StockNews.com